secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0000950170-22-023882
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics Q3 2022: Cash $106.4M; ongoing epetraborole trial; NIAID contract up to $17.8M
--------------------------------------------------------------------------------

- Cash, cash equivalents and investments totaled $106.4M as of Sep 30, 2022; expected to fund operations through mid-2024.
- R&D expenses increased vs. Q3 2021 due to license fee, clinical activity, and personnel costs.
- Enrollment ongoing in pivotal Phase 2/3 trial of epetraborole for treatment-refractory MAC lung disease; Phase 2 top-line data expected ~9 months after enrollment completion.
- Awarded up to $17.8M NIAID contract to develop epetraborole for acute systemic melioidosis.
- Phase 1 study in Japanese subjects supports 500mg once-daily dose regardless of ADH genotype.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000095017022023882/0000950170-22-023882-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000095017022023882/antx-20221109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-023882

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer